We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication.
- Authors
Huo, Yu-Jia; Xu, Peng-Peng; Fu, Di; Yi, Hong-Mei; Huang, Yao-Hui; Wang, Li; Wang, Nan; Ji, Meng-Meng; Liu, Qing-Xiao; Shi, Qing; Wang, Shuo; Cheng, Shu; Feng, Yan; Zhao, Wei-Li
- Abstract
Based on in vitro data that BV enhanced efficacy in three molecular subtypes of CD30 + DLBCL, we supposed that BV was able to kill CD30 + tumor cells of DLBCL. D Left and upper panels indicate T-cell activation score and immune escape score, respectively, stratified by 117 CD30 + DLBCL and 268 CD30-DLBCL. 1 A Prevalence of gene mutations in 55 lymphoma-associated genes, along with the P value for the difference in prevalence between 172 CD30 + DLBCL and 464 CD30-DLBCL. CD30 + DLBCL showed higher score in both T-cell activation and immune escape than CD30-DLBCL ( I P i = 0.004 and I P i < 0.001, Fig.
- Subjects
RITUXIMAB; DIFFUSE large B-cell lymphomas; CD30 antigen; TUMOR necrosis factor receptors; CELL adhesion molecules
- Publication
Blood Cancer Journal, 2022, Vol 12, Issue 3, p1
- ISSN
2044-5385
- Publication type
Letter
- DOI
10.1038/s41408-022-00644-2